super nice find over at agora by George Parros. i dont think GP is back from the SH days, but a valuable contributor or at agora... Along with GP, i'll take it upon myself to disseminate the wonderful news. you know, cause the company can't, or won't, because every single gawddamn finger and thumb is broken over at HQ....
great news....check!
not being promoted by the company....check!
back down we go...... check!
whatevs da fook ur workin on, it had better be big and juicy....ignoring more + exposure.... my gawd the silence is deafening....
i really really want to stay off line, trying to give the benefit to DM and the end of the year....but dilution, no promotion, interesting good news/publications....and a sea of red....
anyways: links..... bolding in the abstract is mine. to help draw the readers attention to the selection of apabetalone. to draw the attention to the article, one must be notified of it's existence, but i digress since that's waaaaaay outta line and thank gawd i patrol Qanon bulletin boards for stock news and advice!!!
https://agoracom.com/ir/Resverlogix/forums/discussion/topics/747917-covid-and-apabetalone/messages/2285108#message
here's the direct link:
https://www.sciencedirect.com/science/article/pii/S2590098620300567
Protein-driven mechanism of multiorgan damage in COVID-19
Abstract
We propose a new plausible mechanism by mean of which SARS-CoV-2 produces extrapulmonary damages in severe COVID-19 patients. The mechanism consist on the existence of vulnerable proteins (VPs), which are (i) mainly expressed outside the lungs; (ii) their perturbations is known to produce human diseases; and (iii) can be perturbed directly or indirectly by SARS-CoV-2 proteins. These VPs are perturbed by other proteins, which are: (i) mainly expressed in the lungs, (ii) are targeted directly by SARS-CoV-2 proteins, (iii) can navigate outside the lungs as cargo of extracellular vesicles (EVs); and (iv) can activate VPs via subdiffusive processes inside the target organ. Using bioinformatic tools and mathematical modeling we identifies 26 VPs and their 38 perturbators, which predict extracellular damages in the immunologic endocrine, cardiovascular, circulatory, lymphatic, musculoskeletal, neurologic, dermatologic, hepatic, gastrointestinal, and metabolic systems, as well as in the eyes. The identification of these VPs and their perturbators allow us to identify 27 existing drugs which are candidates to be repurposed for treating extrapulmonary damage in severe COVID-19 patients. After removal of drugs having undesirable drug-drug interactions we select 7 drugs and one natural product: apabetalone, romidepsin, silmitasertib, ozanezumab, procaine, azacitidine, amlexanox, volociximab, and ellagic acid, whose combinations can palliate the organs and systems found to be damaged by COVID-19. We found that at least 4 drugs are needed to treat all the multiorgan damages, for instance: the combination of romidepsin, silmitasertib, apabetalone and azacitidine.